Starpharma Holdings Ltd has released a press release.
Starpharma receives $7.2 million R&D Tax Incentive refund
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
Story so far
Earlier from Starpharma
- Positive DEP Cabazitaxel Phase 2 Results in Multiple Cancer
- DEP irinotecan clinical data presented at AACR meeting
- DEP irinotecan combination data presentation
- VIRALEZ UK COVID-19 Clinical Study Completes Recruitment
- Positive DEP irinotecan clinical results presentation
Later from Starpharma
- Starpharma announces new CEO, Ms Cheryl Maley
- AGM Chairman's address and CEO presentation
- Positive DEP docetaxel Phase 2 results
- VivaGel BV sales and distribution agreement MENA region
- Viraleze shows antiviral efficacy in COVID-19 patients
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma